IPO

Once plagued by speculation, the SPAC market is maturing. With top-tier banks returning and private equity seeking liquidity, a new era of discipline emerges.

Despite recent clinical setbacks, Alector's $75 million premium offering signals strong institutional faith in its blood-brain barrier technology.

Partners Value Split Corp. just raised $150 million. While retail investors chase a 5.30% yield, the real winner is the corporate parent extracting liquidity.

By turning university hackathons into lucrative B2B talent pipelines, bootstrapped EasyA secures a $1.1 billion valuation ahead of a 2027 direct listing.

The clinical-stage biotech's public debut tests investor appetite for immunology as it funds a novel Treg pipeline into 2029.

Crescent Energy's $1 billion stock offering, heavily anchored by KKR, reveals a structural shift in how North American shale consolidation is financed.

A sharp rise in September CUSIP identifier requests points to an unfreezing IPO pipeline and strategic corporate debt issuance ahead of an active fourth quarter.

Vaxcyte is arming itself with $1 billion in fresh capital to challenge Pfizer and Merck, leveraging a dual-tranche financing strategy to scale manufacturing.

GOA Therapeutics is combining venture backing and institutional placements with retail crowdfunding as part of a $300 million strategy to fund its alcohol poisoning antidote candidate.

Iceland targets 28.5 billion ISK in Q4 benchmark bond issuance, utilizing strategic switch auctions to manage 2027 maturities amid a shifting fiscal landscape.

The Ohio-based manufacturer of mission-critical data center systems hits the Nasdaq, raising $540 million as its private equity backer cashes in on the AI boom.

The SPAC market has grown up. Bluerock's latest $172.5 million vehicle reveals how structured capital is quietly fueling the next wave of enterprise innovation.

Payward's xStocks platform promises global retail investors pre-IPO access to Ōura. But the fine print reveals high fees and synthetic ownership.

ADARx Pharmaceuticals just executed one of 2026's largest biotech debuts. Here is why institutional capital and AbbVie are betting big on the siRNA frontier.

Live Oak's sixth blank-check vehicle signals a matured market where repeat sponsors and boutique banks capitalize on traditional IPO bottlenecks.

First Merchants' $100M subordinated debt offering highlights a savvy capital optimization strategy, swapping Tier 2 debt for equity to fund share repurchases.

By swapping costly 9.0% legacy debt for new Nasdaq-listed notes, Runway Growth Finance is defending its dividend and pivoting toward life sciences stability.

Saratoga Investment Corp. is tapping the retail bond market to swap floating bank debt for fixed 8% notes, trading immediate cost for long-term stability.

Canada’s largest lender is aggressively optimizing its balance sheet, raising $2.6 billion in 48 hours while navigating a shifting post-CDOR rate climate.

Susan Powell investigates The Oak Companies' corporate reorganization, unpacking the hidden costs of using retail equity to retire legacy fund debt.